Skip To Main Content
Kimi Orita on Muck Rack

Kimi Orita

As seen in: Pharma Japan
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Kimi

Contact Kimi, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Kyowa Kirin Says Strong Low-Dose Effect Behind KHK4951 PII Miss

|
By Kimi Orita, Ken Yoshino, Philip Carrigan
| Pharma Japan
By Philip Carrigan We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Open in Who Shared View Duplicates (17) Issue with article?

Recordati Urges Rethink of Zero-Premium Rule on Cost Disclosure

|
By Kimi Orita, Philip Carrigan, Shinya Sato
| Pharma Japan
By Philip Carrigan We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Open in Who Shared View Duplicates (4) Issue with article?

9 Drugs Top 100 Billion Yen in FY2025 Japan Sales; Keytruda Retains Crown: Jiho Tally

|
By Koji Shimomura, Kimi Orita, Kohei Hori
| Pharma Japan
Nine prescription drugs generated domestic sales of more than 100 billion yen in FY2025, three more than a year earlier, according to a Jiho tally, with MSD’s Keytruda (pembrolizumab) retaining the top spot for the third consecutive year. Keytruda sales… To read the full story
Open in Who Shared Issue with article?
See all 10 articles